To determine whether the J591Fab-CY7-PEG20K dual conjugate performed superior for in vivo tumor imaging, we selected low-to-moderate PSMA-expressing 22Rv1 tumors, which can be used to test the detection limits of the two conjugates and to model the heterogeneity of PSMA expression. The gene discussed is FOLH1; the disease is neoplasm.